Liposomal NAD⁺ is sold on one promise: that wrapping the molecule in a fat bubble gets it past your digestion intact, so you can swallow NAD⁺ itself instead of a precursor. It is a genuinely clever idea. It is also, as of today, an idea with no published human trial behind it.
The problem it claims to solve is real
NAD⁺ is a large, charged molecule, and swallowing it does not work well — it is broken down in the gut rather than absorbed whole. That is not marketing spin from a competitor; it is the reason the entire research field went a different way.
Rather than try to deliver NAD⁺ intact, researchers give you a precursor — nicotinamide riboside or nicotinamide mononucleotide — a smaller molecule your cells assemble into NAD⁺ themselves. That approach has randomized human trials showing it reliably raises blood NAD⁺. It is the one thing in this category that is properly established.
Liposomal NAD⁺ proposes to solve the original problem instead of routing around it. If it worked, it would be a real advance. The question is simply whether anyone has shown that it does.
What has actually been tested
We searched PubMed three ways on September 13, 2026, and the results are worth stating precisely rather than summarizing.
A search for liposomal NAD+ clinical trial returned zero results. A search for liposomal nicotinamide riboside oral absorption human returned zero results. A search for liposomal nicotinamide adenine dinucleotide bioavailability returned three, of which exactly one is about liposomal NAD⁺ at all.
That one study is worth reading properly, because it is the whole evidence base and it is not what the supplement pitch implies. Published in 2025, it compared a liposomal NAD⁺ formulation against plain NAD⁺ in cultured human cells — aortic endothelial cells and epidermal keratinocytes — and measured skin penetration ex vivo, in skin explants [1].
Its findings, stated fairly: the liposomal formulation raised intracellular NAD⁺ and cell survival in the endothelial cells but not in the keratinocytes, reduced the number of senescent cells in both, and increased skin penetration of NAD⁺ by about 30% compared with NAD⁺ alone [1]. Those are real results, carefully reported.
They are also, every one of them, results in cells and in pieces of skin. No living person was dosed. And the context is cosmetic dermatology — something applied to skin — not a capsule you swallow. Using it to support an oral supplement is borrowing evidence from a different product, given a different way, for a different purpose.
So does liposomal NAD⁺ get absorbed?
Nobody has published the study that would answer that. There is no human pharmacokinetic trial of oral liposomal NAD⁺ showing that blood NAD⁺ rises after you take it — which is the minimum a product like this needs, and a bar oral precursors cleared years ago.
This is an absence of evidence, not proof that it fails, and we would rather say that plainly than pretend to a certainty nobody has earned. But the burden sits with the seller. When a company charges a premium for a delivery technology, the study establishing that the technology delivers is the thing you are paying for, and it does not exist yet.
How this compares to the alternatives
Set against the other ways to buy NAD⁺, liposomal sits in an awkward spot. It costs more than a plain oral precursor, which has the randomized trials. It costs far less than an injection or an IV drip, which also have no outcome trials — so it is not uniquely unsupported, just unsupported more cheaply.
If the appeal is avoiding needles, an oral precursor already does that, costs less, and has the data. If the appeal is getting NAD⁺ itself rather than a precursor, the honest answer is that no one has shown you are getting it.
What would change our mind
One study, and a fairly ordinary one: give people oral liposomal NAD⁺, measure blood NAD⁺ before and after against a control, and publish it. That is the same design that established oral precursors work, and it is well within reach of any company selling this at scale.
Until someone runs it, treat “enhanced absorption” on a liposomal label as a claim about chemistry rather than a finding about people — and read what NAD⁺ actually is before deciding which form to buy.